SFPM(SZ:002737)2025-01-17 11:45Financial Performance Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between 44 million and 66 million RMB, representing a decrease of 41.03% to 60.68% compared to the previous year's profit of 111.91 million RMB[3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 32 million and 55 million RMB, a decline of 45.19% to 68.11% from the previous year's profit of 100.35 million RMB[3]. - The basic earnings per share is projected to be between 0.75 and 1.13 RMB, down from 1.92 RMB per share in the previous year[3]. Sales and Market Conditions - The decline in overall sales is attributed to the high base effect from the previous year's demand surge for respiratory products, along with high raw material costs impacting gross margins[6]. Operational Strategies - The company continues to maintain strong R&D investment and accelerate the launch of new products despite facing operational pressures[6]. - The company is optimizing its marketing model and streamlining downstream channel inventory to enhance decision-making efficiency, which may have short-term negative impacts on overall performance[6]. Forecast Accuracy - There are currently no significant uncertainties that could affect the accuracy of the performance forecast[7]. - The financial data provided is based on preliminary estimates by the company's finance department and is subject to change pending the annual report[8].